Wire · opportunities
Speed, Discipline, and the New Rules of Biotech Development: Q&A with Stella K. Vnook ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
Declining NIH funding, big pharma's focus on later-stage assets, and global demand for faster clinical proof-of-concept are reshaping early-stage biotech development, requiring founders to adopt leaner, more disciplined strategies integrating commercialization readiness earlier in trial design.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to rethink your trial design with commercialization in mind from the start because the money and pharma interest have shifted downstream. Your best move is to trim costs and accelerate to early human proof to stay competitive in a tougher funding environment.
◆ Coverage
1 source · 24 Aug 2026
◆ Related on Wire
◆ Topics